340 related articles for article (PubMed ID: 19182515)
1. Paths of FGFR-driven tumorigenesis.
Acevedo VD; Ittmann M; Spencer DM
Cell Cycle; 2009 Feb; 8(4):580-8. PubMed ID: 19182515
[TBL] [Abstract][Full Text] [Related]
2. Directionally specific paracrine communication mediated by epithelial FGF9 to stromal FGFR3 in two-compartment premalignant prostate tumors.
Jin C; Wang F; Wu X; Yu C; Luo Y; McKeehan WL
Cancer Res; 2004 Jul; 64(13):4555-62. PubMed ID: 15231666
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate.
Naimi B; Latil A; Fournier G; Mangin P; Cussenot O; Berthon P
Prostate; 2002 Aug; 52(3):245-52. PubMed ID: 12111699
[TBL] [Abstract][Full Text] [Related]
4. Stromal cell heterogeneity in fibroblast growth factor-mediated stromal-epithelial cell cross-talk in premalignant prostate tumors.
Wu X; Jin C; Wang F; Yu C; McKeehan WL
Cancer Res; 2003 Aug; 63(16):4936-44. PubMed ID: 12941818
[TBL] [Abstract][Full Text] [Related]
5. Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications.
Dianat-Moghadam H; Teimoori-Toolabi L
Curr Drug Targets; 2019; 20(8):852-870. PubMed ID: 30648505
[TBL] [Abstract][Full Text] [Related]
6. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer.
Giri D; Ropiquet F; Ittmann M
Clin Cancer Res; 1999 May; 5(5):1063-71. PubMed ID: 10353739
[TBL] [Abstract][Full Text] [Related]
7. Paracrine Fibroblast Growth Factor Initiates Oncogenic Synergy with Epithelial FGFR/Src Transformation in Prostate Tumor Progression.
Li Q; Ingram L; Kim S; Beharry Z; Cooper JA; Cai H
Neoplasia; 2018 Mar; 20(3):233-243. PubMed ID: 29444487
[TBL] [Abstract][Full Text] [Related]
8. Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation.
Freeman KW; Gangula RD; Welm BE; Ozen M; Foster BA; Rosen JM; Ittmann M; Greenberg NM; Spencer DM
Cancer Res; 2003 Oct; 63(19):6237-43. PubMed ID: 14559809
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor receptors: multifactorial-contributors to tumor initiation and progression.
Feng S; Zhou L; Nice EC; Huang C
Histol Histopathol; 2015 Jan; 30(1):13-31. PubMed ID: 25053532
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factors and their receptors in cancer.
Wesche J; Haglund K; Haugsten EM
Biochem J; 2011 Jul; 437(2):199-213. PubMed ID: 21711248
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologically targeting the myristoylation of the scaffold protein FRS2α inhibits FGF/FGFR-mediated oncogenic signaling and tumor progression.
Li Q; Alsaidan OA; Ma Y; Kim S; Liu J; Albers T; Liu K; Beharry Z; Zhao S; Wang F; Lebedyeva I; Cai H
J Biol Chem; 2018 Apr; 293(17):6434-6448. PubMed ID: 29540482
[TBL] [Abstract][Full Text] [Related]
12. Targeting fibroblast growth factor receptor signaling inhibits prostate cancer progression.
Feng S; Shao L; Yu W; Gavine P; Ittmann M
Clin Cancer Res; 2012 Jul; 18(14):3880-8. PubMed ID: 22573348
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications.
Helsten T; Schwaederle M; Kurzrock R
Cancer Metastasis Rev; 2015 Sep; 34(3):479-96. PubMed ID: 26224133
[TBL] [Abstract][Full Text] [Related]
14. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
[TBL] [Abstract][Full Text] [Related]
15. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
Roskoski R
Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
[TBL] [Abstract][Full Text] [Related]
16. Alternative splicing of fibroblast growth factor receptors in human prostate cancer.
Kwabi-Addo B; Ropiquet F; Giri D; Ittmann M
Prostate; 2001 Feb; 46(2):163-72. PubMed ID: 11170144
[TBL] [Abstract][Full Text] [Related]
17. [Development and ligand-protein interaction of small molecule anti-tumor FGFR inhibitors].
Li XL; Qiu R; Li J; Hai L; Wu Y
Yao Xue Xue Bao; 2016 Nov; 51(11):1689-97. PubMed ID: 29908111
[TBL] [Abstract][Full Text] [Related]
18. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.
Gozgit JM; Wong MJ; Moran L; Wardwell S; Mohemmad QK; Narasimhan NI; Shakespeare WC; Wang F; Clackson T; Rivera VM
Mol Cancer Ther; 2012 Mar; 11(3):690-9. PubMed ID: 22238366
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation and co-expression of fibroblast growth factor receptors in human gastric cancer.
Shin EY; Lee BH; Yang JH; Shin KS; Lee GK; Yun HY; Song YJ; Park SC; Kim EG
J Cancer Res Clin Oncol; 2000 Sep; 126(9):519-28. PubMed ID: 11003564
[TBL] [Abstract][Full Text] [Related]
20. FGF signalling in prostate development, tissue homoeostasis and tumorigenesis.
Lin Y; Wang F
Biosci Rep; 2010 Apr; 30(5):285-91. PubMed ID: 20406196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
